Qiagen N.V. (QGEN): Shareholders' Equity
$3.78B
As of 2025-12-31
+2.9%
3-year compound annual growth
+6.2%
5-year compound annual growth
+3.9%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.78B | +5.9% | 2026-03-20, Balance as of period end |
| 2024-12-31 | $3.57B | -6.3% | 2026-03-20, Balance as of period end |
| 2023-12-31 | $3.81B | +9.8% | 2026-03-20, Balance as of period end |
| 2022-12-31 | $3.47B | +12.0% | 2025-03-31, Balance as of period end |
| 2021-12-31 | $3.10B | +10.7% | 2024-03-11, Balance as of period end |
| 2020-12-31 | $2.80B | +10.3% | 2023-03-13, Balance as of period end |
| 2019-12-31 | $2.54B | -3.7% | 2022-03-14, Balance as of period end |
| 2018-12-31 | $2.63B | n/a | 2021-03-05, Balance as of period end |
| No annual figure between 2016-12-31 and 2018-12-31. | |||
| 2016-12-31 | $2.61B | +1.6% | 2017-03-06, Balance as of period end |
| 2015-12-31 | $2.57B | -3.2% | 2017-03-06, Balance as of period end |
| 2014-12-31 | $2.65B | -2.4% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $2.71B | 0.0% | 2015-03-02, Balance as of period end |
| 2012-12-31 | $2.71B | +6.5% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $2.55B | +2.9% | 2013-03-04, Balance as of period end |
| 2010-12-31 | $2.48B | +8.1% | 2012-03-27, Balance as of period end |
| 2009-12-31 | $2.29B | +57.6% | 2012-03-27, Balance as of period end |
| 2008-12-31 | $1.45B | n/a | 2011-03-21, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Qiagen N.V. (QGEN) | 2025-12-31 | $3.78B | +5.9% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $8.65B | -20.6% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.16B | -3.7% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $3.25B | +25.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $48.81M | -86.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Novavax Inc (NVAX) | 2025-12-31 | -$127.75M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | -$119.15M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
Compare QGEN, MRNA, EXEL, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗